Toxicogenomics and cancer risk assessment: a framework for key event analysis and dose-response assessment for nongenotoxic carcinogens.
In order to determine a threshold for nongenotoxic carcinogens, the traditional risk assessment approach has been to identify a mode of action (MOA) with a nonlinear dose-response. The dose-response for one or more key event(s) linked to the MOA for carcinogenicity allows a point of departure (POD) to be selected from the most sensitive effect dose or no-effect dose. However, this can be challenging because multiple MOAs and key events may exist for carcinogenicity and oftentimes extensive research is required to elucidate the MOA. In the present study, a microarray analysis was conducted to determine if a POD could be identified following short-term oral rat exposure with two nongenotoxic rodent carcinogens, fenofibrate and methapyrilene, using a benchmark dose analysis of genes aggregated in Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways and Gene Ontology (GO) biological processes, which likely encompass key event(s) for carcinogenicity. The gene expression response for fenofibrate given to rats for 2days was consistent with its MOA and known key events linked to PPARα activation. The temporal response from daily dosing with methapyrilene demonstrated biological complexity with waves of pathways/biological processes occurring over 1, 3, and 7days; nonetheless, the benchmark dose values were consistent over time. When comparing the dose-response of toxicogenomic data to tumorigenesis or precursor events, the toxicogenomics POD was slightly below any effect level. Our results suggest that toxicogenomic analysis using short-term studies can be used to identify a threshold for nongenotoxic carcinogens based on evaluation of potential key event(s) which then can be used within a risk assessment framework.
Bercu
Joel P
JP
Eli Lilly and Company, Lilly Research Laboratories, Health Safety and Environmental, Indianapolis, IN 46285, USA. jsbercu@hotmail.com
Jolly
Robert A
RA
Flagella
Kelly M
KM
Baker
Thomas K
TK
Romero
Pedro
P
Stevens
James L
JL
D000818:Animals; D002273:Carcinogens / Q000008:administration & dosage / Q000633:toxicity*; D006528:Carcinoma, Hepatocellular / Q000139:chemically induced / Q000235:genetics; D004305:Dose-Response Relationship, Drug; D005260:Female; D011345:Fenofibrate / Q000008:administration & dosage / Q000633:toxicity*; D015870:Gene Expression; D008113:Liver Neoplasms / Q000139:chemically induced / Q000235:genetics; D008701:Methapyrilene / Q000008:administration & dosage / Q000032:analysis* / Q000633:toxicity*; D009369:Neoplasms / Q000139:chemically induced* / Q000235:genetics; D019055:No-Observed-Adverse-Effect Level; D020411:Oligonucleotide Array Sequence Analysis; D051381:Rats; D018570:Risk Assessment; D043922:Toxicogenetics / Q000379:methods*
D002273:Carcinogens; D008701:Methapyrilene; D011345:Fenofibrate